Perspective
Nature Reviews Drug Discovery 3, 88-93 (January 2004) | doi:10.1038/nrd1285
Opinion: Challenges of implementing pharmacogenetics in the critical care environment
Bradley D. Freeman1 & Howard L. McLeod2 About the authors
Abstract
The publication of the human genome sequence has generated great enthusiasm for the potential of gene-based technologies to transform many facets of medical care. Pharmacogenetics — for example, the use of an individual's genetic profile to optimize drug prescription — has generated particular interest, but so far most efforts in this field have focused on sub-acute or chronic illnesses, such as cancer and cardiovascular disease. By contrast, little attention has been devoted to the potential of pharmacogenetics in guiding drug selection for acutely ill patients in the critical care environment. Although such an approach has theoretical appeal as a means of enhancing quality and improving outcomes in this setting, several obstacles exist to bringing this technology to clinical fruition.
Author affiliations
- Bradley D. Freeman is at the Department of Surgery, Washington University School of Medicine, 660 S. Euclid Avenue, Box 8109, St Louis, Missouri 63110, USA.
- Howard L. McLeod is at the Department of Medicine, Washington University School of Medicine, 660 S. Euclid Avenue, Box 8109, St Louis, Missouri 63110, USA.
Correspondence to: Bradley D. Freeman1 Email: freemanb@msnotes.wustl.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
A Facile Lentiviral Vector System for Expression of Doxycycline-Inducible shRNAs: Knockdown of the Pre-miRNA Processing Enzyme DroshaMolecular Therapy Original Article
Monocyte deactivation in septic patients: Restoration by IFN-γ treatmentNature Medicine Article (01 Jun 1997)
Cerebral accumulation of Tc-99m ethyl cysteinate dimer (ECD) in severe, transient hypothyroidismJournal of Cerebral Blood Flow & Metabolism Original Article
